Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

Mark Bustoros; Efstathios Kastritis; Romanos Sklavenitis-Pistofidis; Chia Jen Liu; Kalvis Hornburg; Nikolaos Kanellias; Geon Kim; David Liu; Maria Gavriatopoulou; Catherine R. Marinac; Maria Roussou; Magdalini Migkou; Kimberly Noonan; Kaitlen Reyes; Bradley Rivotto; Carl Jannes Neuse; Dimitrios C. Ziogas; Jacob Laubach; Evangelos Terpos; Kenneth C. Anderson; Paul G. Richardson; Irene M. Ghobrial; Meletios A. Dimopoulos

doi:10.1002/ajh.25441

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

Mark Bustoros
, Efstathios Kastritis
, Romanos Sklavenitis-Pistofidis
, Chia Jen Liu
, Kalvis Hornburg
, Nikolaos Kanellias
, Geon Kim
, David Liu
, Maria Gavriatopoulou
, Catherine R. Marinac
, Maria Roussou
, Magdalini Migkou
, Kimberly Noonan
, Kaitlen Reyes
, Bradley Rivotto
, Carl Jannes Neuse
, Dimitrios C. Ziogas
, Jacob Laubach
, Evangelos Terpos
, Kenneth C. Anderson

Paul G. Richardson, Irene M. Ghobrial^*, Meletios A. Dimopoulos

^*Corresponding author for this work

Institute of Emergency and Critical Care Medicine

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Original language	English
Pages (from-to)	E146-E149
Journal	American Journal of Hematology
Volume	94
Issue number	5
DOIs	https://doi.org/10.1002/ajh.25441
State	Published - May 2019

Access to Document

10.1002/ajh.25441

Cite this

Bustoros, M., Kastritis, E., Sklavenitis-Pistofidis, R., Liu, C. J., Hornburg, K., Kanellias, N., Kim, G., Liu, D., Gavriatopoulou, M., Marinac, C. R., Roussou, M., Migkou, M., Noonan, K., Reyes, K., Rivotto, B., Neuse, C. J., Ziogas, D. C., Laubach, J., Terpos, E., ... Dimopoulos, M. A. (2019). Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. American Journal of Hematology, 94(5), E146-E149. https://doi.org/10.1002/ajh.25441

@article{48dfe9e8404749adab8d27573650d3ee,

title = "Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group",

author = "Mark Bustoros and Efstathios Kastritis and Romanos Sklavenitis-Pistofidis and Liu, \{Chia Jen\} and Kalvis Hornburg and Nikolaos Kanellias and Geon Kim and David Liu and Maria Gavriatopoulou and Marinac, \{Catherine R.\} and Maria Roussou and Magdalini Migkou and Kimberly Noonan and Kaitlen Reyes and Bradley Rivotto and Neuse, \{Carl Jannes\} and Ziogas, \{Dimitrios C.\} and Jacob Laubach and Evangelos Terpos and Anderson, \{Kenneth C.\} and Richardson, \{Paul G.\} and Ghobrial, \{Irene M.\} and Dimopoulos, \{Meletios A.\}",

note = "Funding Information: This study was supported in part by National Institutes of Health grant (NIH R01 CA 205954 and F32 CA220859) and Multiple Myeloma Research Foundation (MMRF)—Perelman Family Foundation grant for early detection and prevention of Multiple Myeloma. Funding Information: M.B. has advisory role and received honoraria from Takeda. E.K. has received honoraria and research funding from Amgen, Genesis Pharma, Janssen, Takeda, Prothena, M.A.D. has received honoraria from Amgen, Celgene, Janssen, Takeda. E.T. has received honoraria and research funding from Amgen, Genesis Pharma, Janssen, Takeda. K.C.A. has advisory role in Celgene, Takeda, Bristol-Myers Squibb (BMS), Janssen, Sanofi, and Gilead. K.C.A. is a scientific founder of OncoPep and C4 therapeutics. P.G.R. has a consulting role and has received research funding from Karyopharm, Oncopeptides, Celgene, Takeda, Amgen, and Janssen. I.M.G. has a consulting/advisory role and has received research funding from Celgene, Takeda, BMS, Janssen Pharmaceuticals, and Amgen.",

year = "2019",

month = may,

doi = "10.1002/ajh.25441",

language = "English",

volume = "94",

pages = "E146--E149",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

Bustoros, M, Kastritis, E, Sklavenitis-Pistofidis, R, Liu, CJ, Hornburg, K, Kanellias, N, Kim, G, Liu, D, Gavriatopoulou, M, Marinac, CR, Roussou, M, Migkou, M, Noonan, K, Reyes, K, Rivotto, B, Neuse, CJ, Ziogas, DC, Laubach, J, Terpos, E, Anderson, KC, Richardson, PG, Ghobrial, IM & Dimopoulos, MA 2019, 'Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group', American Journal of Hematology, vol. 94, no. 5, pp. E146-E149. https://doi.org/10.1002/ajh.25441

TY - JOUR

T1 - Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

AU - Bustoros, Mark

AU - Kastritis, Efstathios

AU - Sklavenitis-Pistofidis, Romanos

AU - Liu, Chia Jen

AU - Hornburg, Kalvis

AU - Kanellias, Nikolaos

AU - Kim, Geon

AU - Liu, David

AU - Gavriatopoulou, Maria

AU - Marinac, Catherine R.

AU - Roussou, Maria

AU - Migkou, Magdalini

AU - Noonan, Kimberly

AU - Reyes, Kaitlen

AU - Rivotto, Bradley

AU - Neuse, Carl Jannes

AU - Ziogas, Dimitrios C.

AU - Laubach, Jacob

AU - Terpos, Evangelos

AU - Anderson, Kenneth C.

AU - Richardson, Paul G.

AU - Ghobrial, Irene M.

AU - Dimopoulos, Meletios A.

N1 - Funding Information: This study was supported in part by National Institutes of Health grant (NIH R01 CA 205954 and F32 CA220859) and Multiple Myeloma Research Foundation (MMRF)—Perelman Family Foundation grant for early detection and prevention of Multiple Myeloma. Funding Information: M.B. has advisory role and received honoraria from Takeda. E.K. has received honoraria and research funding from Amgen, Genesis Pharma, Janssen, Takeda, Prothena, M.A.D. has received honoraria from Amgen, Celgene, Janssen, Takeda. E.T. has received honoraria and research funding from Amgen, Genesis Pharma, Janssen, Takeda. K.C.A. has advisory role in Celgene, Takeda, Bristol-Myers Squibb (BMS), Janssen, Sanofi, and Gilead. K.C.A. is a scientific founder of OncoPep and C4 therapeutics. P.G.R. has a consulting role and has received research funding from Karyopharm, Oncopeptides, Celgene, Takeda, Amgen, and Janssen. I.M.G. has a consulting/advisory role and has received research funding from Celgene, Takeda, BMS, Janssen Pharmaceuticals, and Amgen.

PY - 2019/5

Y1 - 2019/5

UR - https://www.scopus.com/pages/publications/85062684005

U2 - 10.1002/ajh.25441

DO - 10.1002/ajh.25441

M3 - Letter

C2 - 30773670

AN - SCOPUS:85062684005

SN - 0361-8609

VL - 94

SP - E146-E149

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 5

ER -

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group

Access to Document

Other files and links

Cite this